Halozyme Therapeutic (HALO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 03-2026 | 12-2025 | 09-2025 | 06-2025 | 03-2025 | |
| Sales | 376,708 | 451,767 | 354,264 | 325,719 | 264,861 |
| Cost of Goods | 79,238 | 78,770 | 55,242 | 46,359 | 48,403 |
| Gross Profit | 297,470 | 372,997 | 299,022 | 279,360 | 216,458 |
| Operating Expenses | 113,191 | 466,658 | 81,343 | 77,278 | 75,326 |
| Operating Income | 184,517 | -92,891 | 217,921 | 202,441 | 141,535 |
| Interest Expense | 5,508 | 4,911 | 4,296 | 4,394 | 4,525 |
| Other Income | 1,318 | -3,047 | 5,333 | 6,891 | 6,818 |
| Pre-tax Income | 180,327 | -100,849 | 218,958 | 204,938 | 143,828 |
| Income Tax | 30,278 | 40,742 | 43,733 | 39,778 | 25,733 |
| Net Income Continuous | 150,049 | -141,591 | 175,225 | 165,160 | 118,095 |
| Net Income | $150,049 | $-141,591 | $175,225 | $165,160 | $118,095 |
| EPS Basic Total Ops | 1.27 | -1.17 | 1.49 | 1.36 | 0.96 |
| EPS Basic Continuous Ops | 1.27 | -1.17 | 1.49 | 1.36 | 0.96 |
| EPS Diluted Total Ops | 1.22 | -1.13 | 1.43 | 1.33 | 0.93 |
| EPS Diluted Continuous Ops | 1.22 | -1.14 | 1.43 | 1.33 | 0.93 |
| EPS Diluted Before Non-Recurring Items | 1.48 | -0.35 | 1.63 | 1.47 | 1.03 |
| EBITDA(a) | $220,465 | $-64,357 | $239,842 | $223,661 | $162,121 |